Oropharyngeal Administration of Mother's Colostrum for Premature Infants (NS-72393-360)
Infection, Enterocolitis, Necrotizing, Ventilator-associated Pneumonia
About this trial
This is an interventional prevention trial for Infection focused on measuring oropharyngeal, colostrum, mother's milk, premature, neonate, infection, necrotizing enterocolitis, ventilator-associated pneumonia, breastmilk, human milk, late-onset sepsis, microbiome, antioxidant, enteral feeds
Eligibility Criteria
Inclusion Criteria:
Birthweight <1250g Mother plans to pump and provide breastmilk for at least 2 months Absence of severe congenital anomalies Admission to the neonatal intensive care unit within 24 hours after birth Ability to begin protocol within 96 hours of life
Exclusion Criteria:
Gastrointestinal anomaly pH < 7.0 on initial blood gas in NICU Maternal +HIV status Maternal drug or substance use that precludes infant from receiving mother's milk Tracheoesophageal fistula
Sites / Locations
- South Miami Hospital
- NorthShore University health System
- Advocate Children's Hospital-Park Ridge
- Morristown Medical Center
- Betty Cameron Women & Children's Hospital
Arms of the Study
Arm 1
Arm 2
Experimental
Placebo Comparator
oropharyngeal mother's milk
oropharyngeal sterile water
0.2 mL every 2 hours for 48 hours beginning within 96 hours post-birth, followed by 0.2 mL every 3 hours until 32 weeks post conceptional age
0.2 mL every 2 hours for 48 hours beginning within 96 hours post-birth, followed by 0.2 mL every 3 hours until 32 weeks post conceptional age